Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02767128 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl's Solution in Healthy Volunteers
A Phase 1 study of Iron-refractory, Iron-deficiency Anemia (IRIDA), sponsored by Rockwell Medical Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT02767128 is a Phase 1 study of Iron-refractory, Iron-deficiency Anemia (IRIDA) that has completed, run by Rockwell Medical Technologies. The registered enrollment target is 14 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02767128, a Phase 1 study of Iron-refractory, Iron-deficiency Anemia (IRIDA), has completed, sponsored by Rockwell Medical Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose is to determine the pharmacokinetics (PK) of Triferic iron administered orally in healthy adult volunteers. It is a randomized multiple treatments, single dose study.
Conditions Studied
Interventions
- DRUG Triferic
- DRUG Fer-In-Sol
- DRUG Shohl's solution
Study Locations (1)
Michigan
- Jasper Clinic - Kalamazoo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-04 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02767128
The ClinicalTrials.gov registry entry for NCT02767128 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockwell Medical Technologies, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Iron-refractory, Iron-deficiency Anemia (IRIDA) appearing as the primary indexed condition, and to 3 interventions - of which Triferic is the first listed.
NCT02767128 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT02767128 about?
NCT02767128 is a clinical study titled "Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl's Solution in Healthy Volunteers". The main purpose is to determine the pharmacokinetics (PK) of Triferic iron administered orally in healthy adult volunteers. It is a randomized multiple treatments, single dose study.
What is the current status of trial NCT02767128?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2016-04. Estimated completion is 2016-04.
What conditions does trial NCT02767128 study?
This clinical trial studies the following conditions: Iron-refractory, Iron-deficiency Anemia (IRIDA).
What interventions are being tested in trial NCT02767128?
The interventions under investigation include: Triferic (DRUG), Fer-In-Sol (DRUG), Shohl's solution (DRUG).
Who is sponsoring clinical trial NCT02767128?
This trial is sponsored by Rockwell Medical Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02767128 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.